This Article Full Text Full Text (PDF) All Versions of this Article: 91/4/1410    most recent Author Manuscript (PDF) Submit a related Letter to the Editor View responses Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hennings, J. Articles by Hellman, P. Search for Related Content PubMed PubMed Citation Articles by Hennings, J. Articles by Hellman, P. Related Collections Adrenal and Hypertension Endocrine Oncology

[¹¹C]Metomidate Positron Emission Tomography of Adrenocortical Tumors in Correlation with Histopathological Findings

Departments of Surgery (J.H., P.H.), Radiology (A.S.), and Medical Sciences (O.L.), Uppsala University Hospital and Uppsala Imanet AB (O.L., B.L., M.B.), Uppsala, Sweden

Address all correspondence and requests for reprints to: Dr. Per Hellman, Department of Surgery, University Hospital, SE-751 85 Uppsala, Sweden. E-mail: per.hellman{at}surgsci.uu.se.

Context: Adrenal incidentalomas are common findings necessitating extensive laboratory work-up and repetitive radiological examinations. Positron emission tomography (PET) using ¹¹C-labeled metomidate (MTO) has previously been described as a tool for specific adrenocortical imaging.

Objective: We evaluated 212 MTO-PET examinations in 173 patients to identify its role in the management of adrenal tumors.

Design: Seventy-five histopathological examinations from 73 patients were retrospectively analyzed.

Setting: All examinations were performed at a referral center.

Patients: Patients who were operated or biopsied due to adrenal tumors had histopathological diagnoses of adrenocortical adenoma (n = 26), adrenocortical cancer (ACC; n = 13), adrenocortical hyperplasia (n = 8), pheochromocytoma (n = 6), metastasis (n = 3), and tumors of nonadrenal origin (n = 19).

Main Outcome Measures: The main outcome measures were statistical analyses and findings while scrutinizing images. The hypothesis that MTO-PET is of value in the management of adrenal tumors, especially incidentaloma, was stated before data collection.

Results: Sensitivity was 0.89 and specificity was 0.96 for MTO-PET in proving adrenocortical origin of the lesions. Pheochromocytomas, metastases to the adrenal gland, and nonadrenal masses were all MTO negative. PET measurements using standardized uptake values (SUV) in pathological adrenocortical tissue could differentiate lesions larger than 1–1.5 cm from normal adrenocortical tissue. SUV was higher in aldosterone-hypersecreting adenomas, and the SUV ratio between the tumor and the contralateral gland was significantly higher in all hormonally hypersecreting adenomas as well as in ACC.

Conclusion: MTO-PET is a specific and sensitive method for diagnosing adrenocortical tumors. MTO-PET is useful in the imaging work-up of adrenal incidentalomas and may be beneficial for the examination of patients with primary aldosteronism or ACC.

This article has been cited by other articles:

				S. Hahner, A. Stuermer, M. Kreissl, C. Reiners, M. Fassnacht, H. Haenscheid, F. Beuschlein, M. Zink, K. Lang, B. Allolio, et al. [123I]Iodometomidate for Molecular Imaging of Adrenocortical Cytochrome P450 Family 11B Enzymes J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2358 - 2365. [Abstract] [Full Text] [PDF]

				R. Libe, A. Fratticci, and J. Bertherat Adrenocortical cancer: pathophysiology and clinical management Endocr. Relat. Cancer, March 1, 2007; 14(1): 13 - 28. [Abstract] [Full Text] [PDF]

				W. F. Young Jr. The Incidentally Discovered Adrenal Mass N. Engl. J. Med., February 8, 2007; 356(6): 601 - 610. [Full Text] [PDF]

eLetters: